Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines

An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants

(2013) Christopher B Fox et al.   Expert Review of Vaccines

AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial

(2013) Janet E McElhaney et al.   LANCET INFECTIOUS DISEASES

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect

(2013) Samuele Calabro et al.   VACCINE

Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies

(2013) Eric Destexhe et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

(2012) Nathalie Garçon et al.   Expert Review of Vaccines

Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons

(2012) L. A. Jackson et al.   JOURNAL OF INFECTIOUS DISEASES

Prediction and prevention of the next pandemic zoonosis

(2012) Stephen S Morse et al.   LANCET

Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age

(2012) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study

(2011) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

(2011) S. Khurana et al.   Science Translational Medicine

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity

(2011) Sandra Morel et al.   VACCINE

Influenza vaccine immunology

(2010) Philip R. Dormitzer et al.   IMMUNOLOGICAL REVIEWS

Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults

(2010) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway

(2009) R Do et al.   CLINICAL GENETICS

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data

(2009) Geert Leroux-Roels   EXPERT OPINION ON BIOLOGICAL THERAPY

Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges

(2009) Luc Hessel et al.   Influenza and Other Respiratory Viruses

Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults

(2009) Daniel Wai-Sing Chu et al.   VACCINE

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial

(2009) François Roman et al.   VACCINE

Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study

(2009) Isabel Leroux-Roels et al.   VACCINE

Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins

(2008) Ioannis D. Dimitriou et al.   IMMUNOLOGICAL REVIEWS

Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine

(2008) Benoît Baras et al.   PLoS One

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial

(2008) Hans C. Rümke et al.   VACCINE